nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

23.11.2022 | Invited Review

Management of cancer pain due to bone metastasis

verfasst von: Daisuke Takei, Keita Tagami

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Bone metastases frequently occur in patients with cancer. Skeletal-related events (SREs), including pain, impaired mobility, hypercalcemia, pathological fracture, spinal cord and nerve root compression, and bone marrow infiltration, can decrease the quality of life of the patients and increase the risk of morbidity. The mechanism of pain due to bone metastasis is complicated and involves various interactions among tumor cells, bone cells, activated inflammatory cells, and bone-innervating neurons. Cancer pain due to bone metastasis can be crippling and a chronic state that causes sarcopenia. For pain management, it is important to diagnose whether the pain is based on background pain or breakthrough pain due to bone metastasis. In addition, the management goal of cancer pain due to bone metastasis is not only to achieve pain relief but also to prevent pain progression and SREs. Pain mechanisms should be applied to achieve optimal management. This review aims to discuss the mechanisms of cancer pain due to bone metastasis and review the recommended drug therapies.

Zhu XC, Zhang JL, Ge CT, Yu YY, Wang P, Yuan TF, Fu CY (2015) Advances in cancer pain from bone metastasis. Drug Des Dev Ther 9:4239–4245

Huang JF, Shen J, Li X, Rengan R, Silvestris N, Wang M, Derosa L, Zheng X, Belli A, Zhang XL, Li YM, Wu A (2020) Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med 8:482PubMedPubMedCentralCrossRef

Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129:495–503PubMedCrossRef

Harris SR (2016) Differentiating the causes of spontaneous rib fracture after breast cancer. Clin Breast Cancer 16:431–436PubMedCrossRef

Kane CM, Hoskin P, Bennett MI (2015) Cancer induced bone pain. BMJ 350:h315PubMedCrossRef

Milgrom DP, Lad NL, Koniaris LG, Zimmers TA (2017) bone pain and muscle weakness in cancer patients. Curr Osteoporos Rep 15:76–87PubMedPubMedCentralCrossRef

Chambard L, Girard N, Ollier E, Rousseau JC, Duboeuf F, Carlier MC, Brevet M, Szulc P, Pialat JB, Wegrzyn J, Clezardin P, Confavreux CB (2018) Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone 108:202–209PubMedCrossRef

Dohzono S, Sasaoka R, Takamatsu K, Hoshino M, Nakamura H (2020) Low paravertebral muscle mass in patients with bone metastases from lung cancer is associated with poor prognosis. Support Care Cancer 28:389–394PubMedCrossRef

Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef

10.

Zaporowska-Stachowiak I, Łuczak J, Hoffmann K, Stachowiak K, Bryl W, Sopata M (2017) Managing metastatic bone pain: new perspectives, different solutions. Biomed Pharmacother 93:1277–1284PubMedCrossRef

11.

Gdowski AS, Ranjan A, Vishwanatha JK (2017) Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res 36:108PubMedPubMedCentralCrossRef

12.

Zajączkowska R, Kocot-Kępska M, Leppert W, Wordliczek J (2019) Bone pain in cancer patients: mechanisms and current treatment. Int J Mol Sci 20:6047PubMedPubMedCentralCrossRef

13.

Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F (2017) Bone metastases: an overview. Oncol Rev 11:321PubMedPubMedCentral

14.

O’Sullivan GJ, Carty FL, Cronin CG (2015) Imaging of bone metastasis: an update. World J Radiol 7:202–211PubMedPubMedCentralCrossRef

15.

Rosenthal DI (1997) Radiologic diagnosis of bone metastases. Cancer 80:1595–1607PubMedCrossRef

16.

Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, Reiser MF, Baur-Melnyk A (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949PubMedCrossRef

17.

Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M (2008) Translational medicine: cancer pain mechanisms and management. Br J Anaesth 101:87–94PubMedCrossRef

18.

Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 23:129–138PubMed

19.

Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R (2009) Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 144:35–42PubMedCrossRef

20.

Kachooei AR, Ebrahimzadeh MH, Erfani-Sayyar R, Salehi M, Salimi E, Razi S (2015) Short form-mcgill pain questionnaire-2 (SF-MPQ-2): a cross-cultural adaptation and validation study of the persian version in patients with knee osteoarthritis. Arch Bone Jt Surg 3:45–50PubMedPubMedCentral

21.

Cleeland CS (2009) The brief pain inventory user guide. The University of Texas MD Anderson Cancer Center, Houston, TX

22.

Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, ESMO Guidelines Committee (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 29:iv166–iv191PubMedCrossRef

23.

World Health Organization: WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents 2018

24.

Mawatari H, Shinjo T, Morita T, Kohara H, Yomiya K (2022) Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese society of palliative medicine. J Palliat Med 25:1095–1114PubMedCrossRef

25.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738–746PubMedCrossRef

26.

Filippiadis DK, Yevich S, Deschamps F, Jennings JW, Tutton S, Kelekis A (2019) The role of ablation in cancer pain relief. Curr Oncol Rep 21:105PubMedCrossRef

27.

Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP et al (2004) Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22:300–306PubMedCrossRef

28.

Liu Z, Xu Y, Liu ZL, Tian YZ, Shen XH (2017) Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bonecancerpain: a randomized controlled trial. Int J Clin Oncol 22:980–985PubMedCrossRef

29.

Yousef AA, Alzeftawy AE (2019) The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study. Support Care Cancer 27:2171–2177PubMedCrossRef

30.

Joint Formulary Committee (2018) British National Formulary (BNF), No.75. Pharmaceutical Press, London

31.

Mystakidou K, Katsouda E, Kouloulias V, Kouvaris J, Tsiatas M, Vlahos L (2005) Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain. J Opioid Manag 1:204–210PubMedCrossRef

32.

Sima L, Fang WX, Wu XM, Li F (2012) Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther 37:27–31PubMedCrossRef

33.

Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O’Brien T, Morlion B, Tack J (2019) Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J 7:7–20PubMedCrossRef

34.

Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with the use of morphine and opiates. J Intern Med 260:76–87PubMedCrossRef

35.

Thonsantia J, Waikakul W, Wongvikrom W, Sihaban K (2014) Gabapentin as an adjuvant analgesic with opioids for the management of metastatic bone pain: randomized, double - blind, placebo - controlled crossover trial. Thai J Anesthesiol 40:237–252

36.

Sjolund KF, Yang R, Lee KH, Resnick M (2013) Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Ther 2:37–48PubMedPubMedCentralCrossRef

37.

Nishihara M, Arai YC, Yamamoto Y, Nishida K, Arakawa M, Ushida T, Ikeuchi M (2013) Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician 16:E547-552PubMed

38.

Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002:CD002068PubMedPubMedCentral

39.

Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A (2015) A multicenter randomized trial of Ibandronate compared with single-dose radiotherapy for localized metastatic bone pain in prostate cancer. J Natl Cancer Inst 107:djv197PubMedCrossRef

40.

Gralow J, Tripathy D (2007) Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manag 33:462–472CrossRef

41.

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 48:2993–3000PubMedCrossRef

42.

Clohisy DR, Mantyh PW (2004) Bone cancer pain and the role of RANKL/OPG. J Musculoskelet Neuronal Interact 4:293–300PubMed

43.

Lipton A, Jun S (2008) RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2:197–203PubMedCrossRef

44.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21:3497–3507CrossRef

45.

Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, American Society of Clinical Oncology (2011) American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in meta-static breast cancer. J Clin Oncol 29:1221–1227PubMedCrossRef

46.

Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW (2018) Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain 159:1814–1823PubMedPubMedCentralCrossRef

47.

Edwards KA, Havelin JJ, Mcintosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW, Streicher JM (2018) A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain. J Pain 19:612–625PubMedCrossRef

48.

Grenald SA, Doyle TM, Zhang H, Slosky LM, Chen Z, Largent-Milnes TM, Spiegel S, Vanderah TW, Salvemini D (2017) Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. Pain 158:1733–1742PubMedPubMedCentralCrossRef

Titel: Management of cancer pain due to bone metastasis
verfasst von: Daisuke Takei
Keita Tagami
Publikationsdatum: 23.11.2022
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 3/2023
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01382-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Secreted microRNAs in bone metastasis

Immunotherapy as a potential treatment approach for currently incurable bone metastasis

Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis

Cancer and bone: friendly and hostile relationship

Management of bone metastasis in prostate cancer